Hernández Greco, Ramírez Jorge L, Pedroza-Torres Abraham, Herrera Luis A, Jiménez-Ríos Miguel A
Translation and Cancer Laboratory, Unit of Biomedical Research on Cancer, National Institute of Cancer, Mexico City, Mexico.
Cátedra-CONACyT Program, Hereditary Cancer Clinic, National Institute of Cancer, Mexico City, Mexico.
Front Genet. 2019 Jan 30;10:14. doi: 10.3389/fgene.2019.00014. eCollection 2019.
Prostate cancer (PCa) is the second most prevalent cancer in men worldwide. Despite the advances understanding the molecular processes driving the onset and progression of this disease, as well as the continued implementation of screening programs, PCa still remains a significant cause of morbidity and mortality, in particular in low-income countries. It is only recently that defects of the translation process, i.e., the synthesis of proteins by the ribosome using a messenger (m)RNA as a template, have begun to gain attention as an important cause of cancer development in different human tissues, including prostate. In particular, the initiation step of translation has been established to play a key role in tumorigenesis. In this review, we discuss the state-of-the-art of three key aspects of protein synthesis in PCa, namely, misexpression of translation initiation factors, dysregulation of the major signaling cascades regulating translation, and the therapeutic strategies based on pharmacological compounds targeting translation as a novel alternative to those based on hormones controlling the androgen receptor pathway.
前列腺癌(PCa)是全球男性中第二常见的癌症。尽管在理解驱动这种疾病发生和发展的分子过程方面取得了进展,并且筛查项目也在持续实施,但PCa仍然是发病和死亡的重要原因,尤其是在低收入国家。直到最近,翻译过程的缺陷,即核糖体以信使(m)RNA为模板合成蛋白质的过程,才开始作为包括前列腺在内的不同人体组织中癌症发展的一个重要原因而受到关注。特别是,翻译起始步骤已被确定在肿瘤发生中起关键作用。在这篇综述中,我们讨论了前列腺癌蛋白质合成三个关键方面的最新进展,即翻译起始因子的错误表达、调节翻译的主要信号级联的失调,以及基于靶向翻译的药理化合物的治疗策略,作为基于控制雄激素受体途径的激素的治疗方法的一种新选择。